• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Stocks That Hit 52-Week Lows On Thursday

    6/2/22 1:27:44 PM ET
    $ACOR
    $ADN
    $AERI
    $AFIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Machinery/Components
    Miscellaneous
    Get the next $ACOR alert in real time by email

     

    During the Thursday's session, 100 stocks hit new 52-week lows.

    Areas of Significance In Today's 52-Week Lows:

    • Medtronic (NYSE:MDT) was the largest firm by market cap to set a new 52-week low.
    • Acorda Therapeutics (NASDAQ:ACOR) was the smallest company by market cap to set a new 52-week low.
    • Immunic (NASDAQ:IMUX)'s stock moved significantly downwards, trading down 43.14% to reach a new 52-week low.
    • Sutro Biopharma (NASDAQ:STRO) was the most promising stock of the group, with shares actually trading up 0.0% to bounce back after reaching its new 52-week low.

    On Thursday, the following stocks set new 52-week lows:

    • Medtronic (NYSE:MDT) shares were up 0.44% for the day, having made a 52-week low of $96.12.
    • Healthpeak Properties (NYSE:PEAK) shares hit a yearly low of $28.55. The stock was down 1.5% on the session.
    • James Hardie Industries (NYSE:JHX) stock drifted down 0.56% on Thursday morning to hit a new 52-week low of $24.44.
    • Ciena (NYSE:CIEN) shares set a new yearly low of $46.60 this morning. The stock was down 5.0% on the session.
    • Carvana (NYSE:CVNA) shares reached a new 52-week low of $25.31 on Thursday morning, moving up 6.08%.
    • Empire State Realty OP (NYSE:FISK) shares were down 5.16% for the day, having made a 52-week low of $7.41.
    • PTC Therapeutics (NASDAQ:PTCT) shares were down 3.71% for the day, having made a 52-week low of $27.05.
    • Canopy Gwth (NASDAQ:CGC) shares reached a new 52-week low of $4.56 on Thursday morning, moving up 1.17%.
    • Xencor (NASDAQ:XNCR) stock set a new 52-week low of $21.08 on Thursday, moving down 1.33%.
    • Celldex Therapeutics (NASDAQ:CLDX) shares set a new 52-week low of $21.68. The stock traded down 2.42%.
    • Iovance Biotherapeutics (NASDAQ:IOVA) stock hit a yearly low of $6.18. The stock was up 1.02% for the day.
    • Community Health Systems (NYSE:CYH) shares hit a yearly low of $4.96. The stock was up 0.45% on the session.
    • Big Lots (NYSE:BIG) shares were up 3.58% for the day, having made a 52-week low of $22.29.
    • Bright Green (NASDAQ:BGXX) stock hit a new 52-week low of $3.31. The stock was up 13.0% on the session.
    • Gladstone Land (NASDAQ:LANDM) stock drifted down 0.16% on Thursday morning to hit a new 52-week low of $25.15.
    • PMV Pharma (NASDAQ:PMVP) shares were up 4.26% for the day, having made a 52-week low of $11.19.
    • Coherus BioSciences (NASDAQ:CHRS) shares set a new yearly low of $7.01 this morning. The stock was down 2.38% on the session.
    • RCI Hospitality Holdings (NASDAQ:RICK) stock broke to a new 52-week low of $49.50 on Thursday. Shares of the company traded up 2.94%.
    • AnaptysBio (NASDAQ:ANAB) shares hit a yearly low of $18.20. The stock was down 2.22% on the session.
    • MVB Financial (NASDAQ:MVBF) stock hit a yearly low of $36.35. The stock was down 0.33% for the day.
    • Inhibrx (NASDAQ:INBX) shares set a new yearly low of $10.92 this morning. The stock was down 0.71% on the session.
    • Innovid (NYSE:CTV) stock set a new 52-week low of $2.99 on Thursday, moving down 12.43%.
    • D-MARKET Electronic (NASDAQ:HEPS) stock hit a yearly low of $1.17. The stock was down 3.63% for the day.
    • Ouster (NYSE:OUST) shares fell to $2.01 on Thursday, setting a new 52-week low with a shift of up 2.96%.
    • OrganiGram Holdings (NASDAQ:OGI) shares set a new yearly low of $1.08 this morning. The stock was up 2.7% on the session.
    • BARK (NYSE:BARK) shares set a new 52-week low of $1.90. The stock traded down 5.73%.
    • Cepton (NASDAQ:CPTN) shares made a new 52-week low of $2.26 on Thursday. The stock was down 2.55% for the day.
    • LexinFintech Holdings (NASDAQ:LX) stock hit a new 52-week low of $1.84. The stock was down 0.26% on the session.
    • Centessa Pharmaceuticals (NASDAQ:CNTA) stock hit a new 52-week low of $3.59. The stock was down 19.67% on the session.
    • SeaSpine Holdings (NASDAQ:SPNE) shares hit a yearly low of $7.61. The stock was down 0.38% on the session.
    • Oaktree Acquisition (NYSE:OACB) shares were down 8.13% for the day, having made a 52-week low of $8.96.
    • Conn's (NASDAQ:CONN) stock hit a new 52-week low of $11.15. The stock was down 10.14% on the session.
    • Aerie Pharmaceuticals (NASDAQ:AERI) stock achieved a new 52-week low on Thursday morning, hitting $4.81 and moving up 2.83%.
    • Fathom Digital Mfg (NYSE:FATH) stock achieved a new 52-week low on Thursday morning, hitting $4.66 and moving down 1.87%.
    • Dyne Therapeutics (NASDAQ:DYN) shares made a new 52-week low of $4.30 on Thursday. The stock was up 2.05% for the day.
    • Airspan Networks Hldgs (AMEX:MIMO) shares fell to $2.15 on Thursday, setting a new 52-week low with a shift of up 4.33%.
    • bluebird bio (NASDAQ:BLUE) stock hit $2.87 on Thursday morning, setting a new 52-week low for a change of up 1.18%.
    • Macrogenics (NASDAQ:MGNX) stock set a new 52-week low of $3.26 on Thursday, moving up 0.3%.
    • POET Technologies (NASDAQ:POET) shares hit a yearly low of $5.32. The stock was up 2.77% on the session.
    • Sutro Biopharma (NASDAQ:STRO) shares fell to $4.13 on Thursday, setting a new 52-week low with a shift of 0.0% (flat).
    • Jounce Therapeutics (NASDAQ:JNCE) shares reached a new 52-week low of $3.59 on Thursday morning, moving up 1.37%.
    • Viking Therapeutics (NASDAQ:VKTX) stock hit $2.10 on Thursday morning, setting a new 52-week low for a change of up 1.41%.
    • Personalis (NASDAQ:PSNL) stock hit a new 52-week low of $3.51. The stock was up 0.97% on the session.
    • XBiotech (NASDAQ:XBIT) stock achieved a new 52-week low on Thursday morning, hitting $5.18 and moving up 4.61%.
    • BYND Cannasoft Enterprise (NASDAQ:BCAN) stock hit $4.05 on Thursday morning, setting a new 52-week low for a change of down 7.22%.
    • First Community (NASDAQ:FCCO) shares hit a yearly low of $18.01. The stock was down 0.76% on the session.
    • United Security (NASDAQ:UBFO) shares set a new 52-week low of $7.24. The stock traded down 1.49%.
    • NeuroPace (NASDAQ:NPCE) shares set a new 52-week low of $4.90. The stock traded down 1.62%.
    • Paratek Pharmaceuticals (NASDAQ:PRTK) shares set a new yearly low of $1.60 this morning. The stock was up 0.8% on the session.
    • So-Young Intl (NASDAQ:SY) stock hit a yearly low of $0.95. The stock was up 1.04% for the day.
    • Electric Last Mile Solns (NASDAQ:ELMS) stock hit a yearly low of $0.56. The stock was down 1.48% for the day.
    • Advent Technologies Hldgs (NASDAQ:ADN) stock drifted up 6.15% on Thursday morning to hit a new 52-week low of $1.26.
    • Centogene (NASDAQ:CNTG) shares reached a new 52-week low of $2.56 on Thursday morning, moving down 8.57%.
    • Kirkland's (NASDAQ:KIRK) stock broke to a new 52-week low of $4.75 on Thursday. Shares of the company traded down 3.99%.
    • Atreca (NASDAQ:BCEL) shares set a new yearly low of $1.51 this morning. The stock was down 3.77% on the session.
    • BioVie (NASDAQ:BIVI) shares were down 1.71% for the day, having made a 52-week low of $2.25.
    • Codiak BioSciences (NASDAQ:CDAK) shares were up 1.2% for the day, having made a 52-week low of $2.48.
    • Visionary Education Tech (NASDAQ:VEDU) shares set a new 52-week low of $1.33. The stock traded down 6.12%.
    • iBio (AMEX:IBIO) stock dropped to a yearly low on Thursday of $0.22. Shares traded down 0.57%.
    • Elevation Oncology (NASDAQ:ELEV) shares made a new 52-week low of $2.08 on Thursday. The stock was down 2.76% for the day.
    • Athenex (NASDAQ:ATNX) stock hit a new 52-week low of $0.42. The stock was down 2.45% on the session.
    • Aquestive Therapeutics (NASDAQ:AQST) stock hit a new 52-week low of $0.95. The stock was down 1.75% on the session.
    • Sera Prognostics (NASDAQ:SERA) shares were down 2.27% for the day, having made a 52-week low of $1.28.
    • Helbiz (NASDAQ:HLBZ) stock hit $0.91 on Thursday morning, setting a new 52-week low for a change of down 0.95%.
    • Spero Therapeutics (NASDAQ:SPRO) stock hit $1.03 on Thursday morning, setting a new 52-week low for a change of down 3.57%.
    • Renovacor (AMEX:RCOR) shares hit a yearly low of $1.68. The stock was down 7.18% on the session.
    • T2 Biosystems (NASDAQ:TTOO) shares hit a yearly low of $0.19. The stock was down 2.9% on the session.
    • TRACON Pharma (NASDAQ:TCON) shares reached a new 52-week low of $1.60 on Thursday morning, moving down 1.62%.
    • Regis (NYSE:RGS) stock broke to a new 52-week low of $0.67 on Thursday. Shares of the company traded down 0.58%.
    • Cumberland (NASDAQ:CPIX) shares reached a new 52-week low of $1.99 on Thursday morning, moving down 4.78%.
    • Lixiang Education Hldg (NASDAQ:LXEH) stock hit a new 52-week low of $1.90. The stock was down 8.09% on the session.
    • Assure Hldgs (NASDAQ:IONM) stock set a new 52-week low of $1.55 on Thursday, moving down 7.54%.
    • Medigus (NASDAQ:MDGS) stock hit a yearly low of $0.78. The stock was up 1.22% for the day.
    • Panbela Therapeutics (NASDAQ:PBLA) stock dropped to a yearly low on Thursday of $1.44. Shares traded down 0.19%.
    • Acutus Medical (NASDAQ:AFIB) shares set a new yearly low of $0.61 this morning. The stock was down 3.22% on the session.
    • TC BioPharm (Holdings) (NASDAQ:TCBP) stock dropped to a yearly low on Thursday of $0.60. Shares traded down 5.36%.
    • WiSA Technologies (NASDAQ:WISA) stock broke to a new 52-week low of $0.63 on Thursday. Shares of the company traded down 13.87%.
    • Sharps Technology (NASDAQ:STSS) stock hit a yearly low of $1.03. The stock was down 1.83% for the day.
    • Histogen (NASDAQ:HSTO) stock achieved a new 52-week low on Thursday morning, hitting $0.13 and moving down 12.21%.

    Be sure to monitor Benzinga for the news traders need! And for even more up-to-date info on 52-week lows and highs, check out Benzinga Pro. This cutting-edge market research platform alerts traders of which stocks are trading near their 52-week highs and lows each morning - and delivers lots of other actionable data. Learn more here.

    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $ADN
    $AERI
    $AFIB

    CompanyDatePrice TargetRatingAnalyst
    Celldex Therapeutics Inc.
    $CLDX
    4/20/2026$45.00Underweight → Overweight
    Barclays
    Immunic Inc.
    $IMUX
    4/17/2026$2.50Buy
    Stifel
    Immunic Inc.
    $IMUX
    4/15/2026Buy → Hold
    D. Boral Capital
    Centessa Pharmaceuticals plc
    $CNTA
    4/13/2026$38.00Buy → Hold
    Truist
    PTC Therapeutics Inc.
    $PTCT
    4/10/2026$108.00Outperform
    Raymond James
    MacroGenics Inc.
    $MGNX
    4/10/2026$9.00Neutral → Buy
    B. Riley Securities
    Inhibrx Biosciences Inc.
    $INBX
    4/8/2026$150.00Buy
    Stifel
    Sutro Biopharma Inc.
    $STRO
    4/7/2026$38.00Outperform
    Leerink Partners
    More analyst ratings

    $ACOR
    $ADN
    $AERI
    $AFIB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Posner Brian S bought $38,700 worth of shares (2,000 units at $19.35), increasing direct ownership by 17% to 13,500 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    3/13/26 4:46:19 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Posner Brian S bought $45,180 worth of shares (3,000 units at $15.06), increasing direct ownership by 35% to 11,500 units (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    3/10/26 5:33:53 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Boulet Virginia bought $136,175 worth of shares (6,500 units at $20.95), increasing direct ownership by 3% to 228,342 units (SEC Form 4)

    4 - Ouster, Inc. (0001816581) (Issuer)

    3/9/26 7:35:06 PM ET
    $OUST
    Industrial Machinery/Components
    Industrials

    $ACOR
    $ADN
    $AERI
    $AFIB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Celldex Therapeutics upgraded by Barclays with a new price target

    Barclays upgraded Celldex Therapeutics from Underweight to Overweight and set a new price target of $45.00

    4/20/26 8:20:25 AM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Stifel initiated coverage on Immunic with a new price target

    Stifel initiated coverage of Immunic with a rating of Buy and set a new price target of $2.50

    4/17/26 8:12:09 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immunic downgraded by D. Boral Capital

    D. Boral Capital downgraded Immunic from Buy to Hold

    4/15/26 7:47:45 AM ET
    $IMUX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ADN
    $AERI
    $AFIB
    SEC Filings

    View All

    SEC Form 144 filed by Dyne Therapeutics Inc.

    144 - Dyne Therapeutics, Inc. (0001818794) (Subject)

    4/23/26 4:46:15 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Dyne Therapeutics Inc.

    144 - Dyne Therapeutics, Inc. (0001818794) (Subject)

    4/23/26 4:45:31 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Dyne Therapeutics Inc.

    144 - Dyne Therapeutics, Inc. (0001818794) (Subject)

    4/23/26 4:45:18 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ADN
    $AERI
    $AFIB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Frichtl Mark exercised 400 shares at a strike of $2.13 and sold $12,000 worth of shares (400 units at $30.00) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Ouster, Inc. (0001816581) (Issuer)

    4/23/26 5:54:33 PM ET
    $OUST
    Industrial Machinery/Components
    Industrials

    CHIEF EXECUTIVE OFFICER Klein Matthew B. sold $202,094 worth of shares (2,850 units at $70.91), decreasing direct ownership by 0.72% to 394,070 units (SEC Form 4) to satisfy withholding tax

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    4/23/26 5:20:06 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Kersten Dirk sold $219,170 worth of shares (10,952 units at $20.01) as part of a pre-agreed trading plan (SEC Form 4)

    4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)

    4/23/26 4:15:03 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ADN
    $AERI
    $AFIB
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    FDA Approval for CIMERLI issued to COHERUS BIOSCIENCES INC

    Submission status for COHERUS BIOSCIENCES INC's drug CIMERLI (SUPPL-5) with active ingredient RANIBIZUMAB-EQRN has changed to 'Approval' on 05/21/2024. Application Category: BLA, Application Number: 761165, Application Classification:

    5/22/24 9:41:01 AM ET
    $CHRS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for LIBERVANT issued to AQUESTIVE THERAPEUTICS INC

    Submission status for AQUESTIVE THERAPEUTICS INC's drug LIBERVANT (ORIG-1) with active ingredient DIAZEPAM has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218623, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    4/29/24 7:48:13 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ADN
    $AERI
    $AFIB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    WALTHAM, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 18 new employees. The awards were made as an inducement material to the new employees' acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 320,900 shares of Dyne's common stock at a per share exercise price equal to the closing price of Dyne's common stock on The Nasdaq

    4/23/26 4:05:00 PM ET
    $DYN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Personalis to Announce First Quarter 2026 Financial Results

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2026 financial results on Thursday, May 7, 2026. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly

    4/23/26 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026

    Pre-randomization Atrioventricular Interval Modulation Therapy ("AVIM Therapy") set-up data from the MODERATO II randomized, prospective, multi-center, double-blind, controlled trial show an immediate average reduction of 13.2 mmHg in office systolic blood pressure ("oSBP")97% of patients experienced an immediate blood pressure reduction of >5 mmHg reduction in oSBP prior to randomizationAVIM Therapy demonstrated the potential to deliver immediate, substantial, and sustained reductions in blood pressure, with evidence of improved diastolic function and reverse cardiac remodelingThe BACKBEAT Global Pivotal Trial, which Orchestra BioMed is actively enrolling as part of a strategic collaboratio

    4/23/26 12:00:00 PM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    $ACOR
    $ADN
    $AERI
    $AFIB
    Leadership Updates

    Live Leadership Updates

    View All

    'There's a Tweed for That': Canopy Growth Announces Tweed Brand Summer Campaign

    New window bags, improved potency, and sharper pricing arrive at retail Victoria Day long weekend Canopy Growth Corporation ("Canopy Growth", "Canopy" or the "Company") (TSX:WEED) (NASDAQ:CGC) today announced a refresh of Tweed, one of Canada's most recognizable cannabis brands, alongside a national summer campaign, "There's a Tweed for That." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260423388138/en/The Tweed summer campaign launches over the Victoria Day long weekend, the traditional kickoff to the Canadian summer, spotlighting Tweed's updated portfolio, including three new flower strains and the popular Quickies pre-ro

    4/23/26 7:30:00 AM ET
    $CGC
    Medicinal Chemicals and Botanical Products
    Health Care

    PMV Pharmaceuticals Announces Board Chair Transition

    PRINCETON, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced a leadership transition on its Board of Directors. Laurie Stelzer, who has served as a member of the Board since 2020, has been appointed Chair of the Board, succeeding Rich Heyman, Ph.D., effective at the Company's 2026 Annual Meeting of Stockholders on June 4, 2026 (the "Meeting"). Dr. Heyman's term as a member and Chair of the Board will expire at the Meeting, and Dr. Heyman will not stand for reelection. Ms. Stelzer brings more than 25

    4/22/26 8:00:00 AM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Regis Corporation Announces Appointment of William "Bill" Charters as Independent Director

    Appointment Adds Perspective from One of the Company's Largest Individual Shareholders with Extensive Investment and Financial Experience Regis Corporation (NASDAQ:RGS), a leading franchisor of haircare salons, today announced the appointment of William "Bill" Charters as an independent member of its Board of Directors, effective April 24, 2026. Mr. Charters brings extensive experience as a public markets investor and financial strategist, with a background in corporate credit, restructurings, and complex transaction execution. His expertise includes evaluating capital structures, advising on corporate strategy, and analyzing franchise-based business models. Susan Lintonsmith, Preside

    4/15/26 6:30:00 AM ET
    $RGS
    Other Consumer Services
    Consumer Discretionary

    $ACOR
    $ADN
    $AERI
    $AFIB
    Financials

    Live finance-specific insights

    View All

    Personalis to Announce First Quarter 2026 Financial Results

    Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its first quarter 2026 financial results on Thursday, May 7, 2026. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The live webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly

    4/23/26 4:01:00 PM ET
    $PSNL
    Medical Specialities
    Health Care

    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

    Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi

    4/23/26 6:15:00 AM ET
    $LGVN
    $LLY
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026

    Conference Call Scheduled for Wednesday, April 29 at 4:30 p.m. Eastern Time SAN DIEGO, April 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter of 2026 after the market close on Wednesday, April 29, 2026. The company will host a conference call to discuss financial results and general corporate updates beginning at 4:30 p.m. Eastern Time on We

    4/22/26 4:35:00 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACOR
    $ADN
    $AERI
    $AFIB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Acutus Medical Inc.

    SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    12/16/24 9:52:56 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Carvana Co.

    SC 13D/A - CARVANA CO. (0001690820) (Subject)

    12/16/24 6:13:26 PM ET
    $CVNA
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    SEC Form SC 13G filed by PMV Pharmaceuticals Inc.

    SC 13G - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    12/12/24 12:29:41 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care